Efficacy and Safety of Upadacitinib After 3 Years of Treatment in Patients With Moderately to Severely Active Ulcerative Colitis: Interim Long-Term Data From the Phase 3 Open-Label Extension Study (U-ACTIVATE)

被引：0
|
作者：
Panaccione, Remo [1 ]
Higgins, Peter [2 ]
Nakase, Hiroshi [3 ]
Glover, Sarah C. [4 ]
Danese, Silvio [5 ]
Colombel, Jean-Frederic [6 ]
Eccleston, Jason [7 ]
Kujawski, Michelle [7 ]
Remple, Valencia [7 ]
Yao, Xuan [7 ]
Suravaram, Smitha [7 ]
Schreiber, Stefan [8 ]
机构：
[1] Univ Calgary, Calgary, AB, Canada
[2] Univ Michigan, Ann Arbor, MI USA
[3] Sapporo Med Univ, Sch Med, Sapporo, Hokkaido, Japan
[4] Tulane Univ, Sch Med, New Orleans, LA USA
[5] Rozzano & Humanitas Univ, Humanitas Clin & Res Ctr IRCCS, Milan, Lombardia, Italy
[6] Icahn Sch Med Mt Sinai, New York, NY USA
[7] AbbVie Inc, N Chicago, IL USA
[8] Univ Hosp, Kiel, Schleswig Holst, Germany
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2024年 / 119卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
S1474
引用
收藏
页码：S1061 / S1062
页数：2
相关论文
共 50 条
  • [1] Efficacy and safety of upadacitinib after 4 years of treatment in patients with moderately to severely active ulcerative colitis: interim long-term data from the phase 3 open-label extension study (U-ACTIVATE)
    Panaccione, R.
    Lichtenstein, G.
    Colombel, J. F.
    Nakase, H.
    Yao, X.
    Klaff, J.
    Kujawski, M.
    Rizzo, L.
    Suravaram, S.
    Vermeire, S.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i80 - i82
  • [2] Safety of upadacitinib in ulcerative colitis: Long-term data from the phase 3 open-label extension study (U-ACTIVATE)
    Panaccione, R.
    Lichtenstein, G.
    Nakase, H.
    Armuzzi, A.
    Kucharzik, T.
    Levy, G.
    Palac, H.
    Kujawski, M.
    Klaff, J.
    Cheon, J. H.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 644 - 646
  • [3] SAFETY OF UPADACITINIB IN ULCERATIVE COLITIS: LONG-TERM DATA FROM THE PHASE 3 OPEN-LABEL EXTENSION STUDY (U-ACTIVATE)
    Panaccione, Remo
    Lichtenstein, Gary R.
    Nakase, Hiroshi
    Armuzzi, Alessandro
    Kucharzik, Torsten
    Levy, Gweneth
    Palac, Hannah
    Kujawski, Michelle
    Klaff, Justin
    Cheon, Jae Hee
    GASTROENTEROLOGY, 2023, 164 (06) : S1100 - S1100
  • [4] Efficacy and safety of retreatment with upadacitinib after treatment interruption in ulcerative colitis: Data from the phase 3 open-label extension study U-ACTIVATE
    Panaccione, R.
    Colombel, J. F.
    Dubinsky, M.
    Hisamatsu, T.
    Remple, V.
    Garrison, A.
    Klaff, J.
    Kujawski, M.
    Vermeire, S.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1812 - I1813
  • [5] Efficacy and safety of retreatment with upadacitinib after treatment interruption in ulcerative colitis: Data from the phase 3 open-label extension study U-ACTIVATE
    Panaccione, Remo
    Colombel, Jean-Frederic
    Dubinsky, Marla
    Hisamatsu, Tadakazu
    Remple, Valencia
    Garrison, Andrew
    Klaff, Justin
    Kujawski, Michelle R.
    Baraty, Brandon
    Vermeire, Severine
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 39 : 165 - 165
  • [6] Corticosteroid-Free Remission Through 3 Years of Upadacitinib Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Data From the Phase 3 Long-Term Extension Study U-ACTIVATE
    Dubinsky, Marla
    Atreya, Raja
    Nakase, Hiroshi
    Kujawski, Michelle
    Crooks, James
    Cheng, Erica
    Klaff, Justin
    Panaccione, Remo
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S764 - S764
  • [7] LONG-TERM SAFETY OF 3 YEARS OF OZANIMOD IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: AN INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION
    Abreu, Maria T.
    Danese, Silvio
    Wolf, Douglas C.
    Canavan, James B.
    Jain, Anjali
    Wu, Hsiuanlin
    Petersen, AnnKatrin
    Charles, Lorna
    Afzali, Anita
    Panaccione, Remo
    GASTROENTEROLOGY, 2023, 164 (06) : S208 - S208
  • [8] Long-term safety of 3 years of ozanimod in moderately to severely active ulcerative colitis: an interim analysis of the True North open-label extension
    Panaccione, R.
    Danese, S.
    Wolf, D. C.
    Canavan, J. B.
    Jain, A.
    Wu, H.
    Petersen, A.
    Charles, L.
    Afzali, A.
    Abreu, M. T.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 534 - 534
  • [9] Efficacy and safety up to 3 years of risankizumab maintenance treatment in patients with moderately to severely active ulcerative colitis: interim results from phase 3 COMMAND open-label extension study
    Atreya, R.
    Louis, E.
    Loftus Jr., E., V
    Rubin, D. T.
    Dubinsky, M.
    Hisamatsu, T.
    Kalabic, J.
    Mendez, P.
    Chen, S.
    Shah, S.
    Morisset, P.
    Duan, W. R.
    Panaccione, R.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i104 - i106
  • [10] Safety of long-term ozanimod treatment for up to 4 years in patients with moderately to severely active Ulcerative Colitis: an interim analysis of the True North open-label extension
    Siegel, C.
    Danese, S.
    Rubin, D. T.
    Sabino, J.
    Long, M. D.
    Cross, R. K.
    Armuzzi, A.
    Blumenstein, I.
    Kobayashi, T.
    Lama, S.
    Charles, L.
    Cetin, V.
    Petersen, A.
    Wu, H.
    Wang, D.
    Jain, A.
    D'Haens, G.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I100 - I101
12345